GSK Product development pipeline March 2015 Pipeline, products and competition Pharmaceuticals and Vaccines product development pipeline Key In-licence or other alliance relationship with third party * Also being developed for indications in another therapeutic area S Month of first submission AMonth of first regulatory approval (for MAA, this is the first EU approval letter) BLABiological Licence Application MAA Marketing Authorisation Application (Europe) NDA New Drug Application (USA) † Phase I Evaluation of clinical pharmacology, usually conducted in volunteers Phase IIDetermination of dose and initial evaluation of efficacy, conducted in a small number of patients Phase IIILarge comparative study (compound versus placebo and/or established treatment) in patients to establish clinical benefit and safety MAA and NDA/BLA regulatory review milestones shown in the table below are those that have been achieved. Future filing dates are not included in this list. Compound Respiratory 2126458 2256294 2862277 961081† + fluticasone furoate 961081† 2245035 2269557 2586881† danirixin fluticasone furoate + umeclidinium losmapimod mepolizumab fluticasone furoate + vilanterol† + umeclidinium mepolizumab Relvar/Breo Ellipta (vilanterol† + fluticasone furoate) vilanterol† mepolizumab Anoro Ellipta (umeclidinium + vilanterol†) Arnuity Ellipta (fluticasone furoate) Incruse Ellipta (umeclidinium) Relvar/Breo Ellipta (vilanterol† + fluticasone furoate) Type Indication Phase phosphoinositide 3 kinase (PI3K) inhibitor soluble epoxide hydrolase (sEH) inhibitor tumour necrosis factor receptor-1 (TNFR1) domain antibody muscarinic acetylcholine antagonist, beta2 agonist (MABA) + glucocorticoid agonist MABA toll-like receptor 7 agonist PI3K inhibitor recombinant human angiotensin converting enzyme 2 CXCR2 chemokine receptor antagonist glucocorticoid agonist + muscarinic acetylcholine antagonist p38 kinase inhibitor (oral) IL5 monoclonal antibody glucocorticoid agonist + long-acting beta2 agonist + muscarinic acetylcholine antagonist idiopathic pulmonary fibrosis chronic obstructive pulmonary disease (COPD) acute lung injury I I I COPD I COPD asthma asthma & COPD acute lung injury II II II II COPD asthma COPD overlap syndrome II II COPD* nasal polyposis* COPD II II III IL5 monoclonal antibody COPD* long-acting beta2 agonist + glucocorticoid agonist COPD – mortality outcomes III III long-acting beta2 agonist IL5 monoclonal antibody muscarinic acetylcholine antagonist + long-acting beta2 agonist COPD severe eosinophilic asthma* COPD III Submitted Approved S: Nov14 A: May14 S: Nov14 A: Dec13 glucocorticoid agonist asthma Approved N/A A: Aug14 muscarinic acetylcholine antagonist COPD* Approved A: Apr14 A:Apr14 long-acting beta2 agonist + glucocorticoid agonist asthma Approved A: Nov13 S: Jun14 N/A Paediatric Vaccines RSV recombinant RSV S. pneumoniae next generation† MMR Mosquirix (Malaria RTS,S)† DTPa-HBV-IPV/Hib† Nimenrix (MenACWY-TT) Achieved regulatory review milestones MAA NDA/BLA I recombinant viral vector recombinant – conjugated respiratory syncytial virus prophylaxis (maternal immunisation) respiratory syncytial virus prophylaxis Streptococcus pneumoniae disease prophylaxis live attenuated recombinant measles, mumps, rubella prophylaxis malaria prophylaxis (Plasmodium falciparum) III (US) Submitted N/A S: Jun14 conjugated diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, haemophilus influenza Neisseria meningitis groups A, C, W & Y disease prophylaxis Approved II (US) Approved N/A conjugated I II A: Apr12 II (US) GSK Product Pipline 2014 Pipeline, products and competition continued Pharmaceuticals and Vaccines product development pipeline continued Compound Type Indication Phase Malaria next generation† NTHi† Tuberculosis† Hepatitis C Ebola† recombinant recombinant recombinant recombinant viral vector recombinant viral vector II II II II III Zoster† recombinant malaria prophylaxis (Plasmodium falciparum) non-typeable Haemophilus influenzae prophylaxis tuberculosis prophylaxis hepatitis C virus prophylaxis prevention of filovirus haemorrhagic fevers caused by Ebola Zaire virus Herpes Zoster prophylaxis treatment of melanoma III HIV integrase inhibitor (long-acting parenteral formulation) HIV integrase inhibitor (long-acting parenteral formulation) HIV integrase inhibitor + reverse transcriptase inhibitors (fixed dose combination) HIV infections II HIV pre-exposure prophylaxis II HIV infections – fixed dose combination Approved bromodomain inhibitor focal adhesion kinase inhibitor PI3K inhibitor enhancer of zeste homologue2 (EZH2) inhibitor ErbB3 monoclonal antibody beta cell maturation antigen antibody drug conjugate lysine-specific demethylase 1 (LSD1) inhibitor fibroblast growth factor ligand trap AKT protein kinase inhibitor multi-kinase angiogenesis inhibitor + PD-1 monoclonal antibody AKT protein kinase inhibitor MEK1/2 inhibitor + BRAF protein kinase inhibitor MEK1/2 inhibitor + BRAF protein kinase inhibitor MEK1/2 inhibitor + BRAF protein kinase inhibitor + human anti-EGFR monoclonal antibody thrombopoietin receptor agonist cancer cancer cancer cancer I I I I cancer multiple myeloma I I cancer I cancer multiple myeloma renal cell cancer I I I ovarian cancer non-small cell lung cancer II II rare cancers II colorectal cancer II acute myeloid leukaemia II CD20 human monoclonal antibody CD20 human monoclonal antibody MEK1/2 inhibitor + BRAF protein kinase inhibitor thrombopoietin receptor agonist chronic lymphocytic leukaemia, use in relapsed patients follicular lymphoma (refractory & relapsed patients) metastatic melanoma, adjuvant therapy III III III myelodysplastic syndromes III multi-kinase angiogenesis inhibitor CD20 human monoclonal antibody MEK1/2 inhibitor MEK1/2 inhibitor + BRAF protein kinase inhibitor thrombopoietin receptor agonist renal cell cancer, adjuvant therapy chronic lymphocytic leukaemia, first line therapy metastatic melanoma metastatic melanoma aplastic anaemia Other Vaccines Antigen-Specific Cancer Immunotherapeutic MAGE-A3 immunotherapeutic† recombinant HIV (ViiV Healthcare) cabotegravir (1265744) cabotegravir (1265744) Triumeq (dolutegravir + abacavir sulphate + lamivudine) Oncology 525762 2256098 2636771 2816126 2849330 2857916 2879552 3052230† afuresertib (2110183) Votrient (pazopanib) + MK-3475† afuresertib (2110183) Mekinist (trametinib)† + Tafinlar (dabrafenib) Mekinist (trametinib)† + Tafinlar (dabrafenib) Mekinist (trametinib)† + Tafinlar (dabrafenib) + panitumumab† Revolade/Promacta (eltrombopag)† Arzerra (ofatumumab)† Arzerra (ofatumumab)† Mekinist (trametinib)† + Tafinlar (dabrafenib) Revolade/Promacta (eltrombopag)† Votrient (pazopanib) Arzerra (ofatumumab)† Mekinist (trametinib)† Mekinist (trametinib)† + Tafinlar (dabrafenib) Revolade/Promacta (eltrombopag)† GSK Product Pipeline 2014 Achieved regulatory review milestones MAA NDA/BLA III A: Sep14 A: Aug14 III Approved Approved Approved A: Jun14 A: Jul14 A: Apr14 A: May13 A: Jan 14 Approved S: Nov14 A: Aug14 Pharmaceuticals and Vaccines product development pipeline continued Compound Type Indication Phase prolyl hydroxylase inhibitor (topical) transient receptor potential cation channel V4 (TRPV4) antagonist selective androgen receptor modulator prolyl hydroxylase inhibitor ileal bile acid transport inhibitor motilin receptor agonist GLP 1 agonist wound healing heart failure I I muscle wasting anaemia associated with chronic renal disease type 2 diabetes & cholestatic pruritus delayed gastric emptying type 1 diabetes I II II II II p38 kinase inhibitor CD3 monoclonal antibody p38 kinase inhibitor oxytocin antagonist GLP 1 agonist focal segmental glomerular sclerosis* new onset type 1 diabetes acute coronary syndrome* threatened pre-term labour type 2 diabetes II II III III Approved A: Mar14 autoimmune disease chronic urticaria I I autoimmune disease autoimmune disease autoimmune disease rheumatoid arthritis I I I I rheumatoid arthritis II transplant rejection* II systemic lupus erythematosus* III vasculitis* III rheumatoid arthritis III amyloidosis I metachromatic leukodystrophy Wiscott-Aldrich syndrome amyotrophic lateral sclerosis II II II III Cardiovascular & Metabolic 1278863 2798745 2881078 1278863 2330672 camicinal Eperzan/Tanzeum (albiglutide) losmapimod otelixizumab losmapimod retosiban Eperzan/Tanzeum (albiglutide) Immuno-inflammation 2618960 2646264 2831781† 2982772 3050002† 3117391† 3196165 (MOR103)† Benlysta (belimumab) Benlysta (belimumab) Benlysta (belimumab) sirukumab† Rare Diseases 2398852† + 23156898† 2696274† 2696275† ozanezumab IL7 receptor monoclonal antibody spleen tyrosine kinase (Syk) inhibitor (topical) LAG3 monoclonal antibody RIP1 kinase inhibitor CCL20 monoclonal antibody macrophage targeted histone deacetylase inhibitor granulocyte macrophage colonystimulating factor monoclonal antibody B lymphocyte stimulator monoclonal antibody (i.v.) B lymphocyte stimulator monoclonal antibody (s.c.) B lymphocyte stimulator monoclonal antibody (i.v.) IL6 human monoclonal antibody (s.c.) 2696273† SAP monoclonal antibody + SAP depleter (CPHPC) ex-vivo stem cell gene therapy ex-vivo stem cell gene therapy neurite outgrowth inhibitor (NOGO-A) monoclonal antibody ex-vivo stem cell gene therapy mepolizumab Volibris (ambrisentan)† IL5 monoclonal antibody (s.c.) endothelin A antagonist adenosine deaminase severe combined immune deficiency (ADA-SCID) eosinophilic granulomatosis with polyangiitis* chronic thromboembolic pulmonary hypertension antiviral maturation inhibitor NS5B polymerase inhibitor type 2 topoisomerase inhibitor 8-aminoquinoline neuraminidase inhibitor (i.v.) HIV infections hepatitis C bacterial infections Plasmodium vivax malaria influenza I I II III III CD20 human monoclonal antibody (s.c.) B lymphocyte stimulator monoclonal antibody (i.v.) CD20 human monoclonal antibody (s.c.) Lp-PLA2 inhibitor neuromyelitis optica* myaesthenia gravis* II II multiple sclerosis* Alzheimer's disease II II Infectious Diseases 2838232 2878175 2140944 tafenoquine† Relenza i.v. (zanamivir)† Neurosciences ofatumumab† Benlysta (belimumab) ofatumumab† rilapladib Achieved regulatory review milestones MAA NDA/BLA A:Apr14 III III GSK Product Pipeline 2014 Pipeline, products and competition continued Pharmaceuticals and Vaccines product development pipeline continued Compound Ophthalmology 933776 Dermatology 1940029 umeclidinium 2894512† chlorhexidine ofatumumab† Toctino (alitretinoin)† Type Indication Phase beta amyloid monoclonal antibody geographic retinal atrophy II stearoyl CoA desaturase 1 inhibitor (topical) muscarinic acetylcholine antagonist (topical) non-steroidal anti-inflammatory cationic polybiguanide (topical) CD20 human monoclonal antibody (s.c.) retinoic acid receptor modulator acne vulgaris hyperhidrosis* atopic dermatitis & psoriasis umbilical cord care pemphigus vulgaris* chronic hand eczema I I II III III III Achieved regulatory review milestones MAA NDA/BLA N/A Brand names appearing in italics are trade marks either owned by and/or licensed to GSK or associated companies. Option-based alliances with third parties that include assets in phase I and phase III development: Company Disease Area Phase Adaptimmune Cancer Research UK ISIS Pharmaceuticals cancer cancer hepatitis B transthyretin-mediated amyloidosis oncology oncology bacterial infection I I I III I II I OncoMed Pharmaceuticals Shionogi This document outlines GlaxoSmithKline’s drug development portfolio. The content of the drug development portfolio will change over time as new compounds progress from discovery to development and from development to the market. Owing to the nature of the drug development process, many of these compounds, especially those in early stages of investigation, may be terminated as they progress through development. For competitive reasons, new projects in pre-clinical development have not been disclosed and some project types may not have been identified. GSK Product Pipeline 2014 Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this document, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’s operations are described under Item 3.D ‘Risk factors’ in the company’s Annual Report on Form 20-F for 2014. Head Office and Registered Office GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS United Kingdom Tel: +44 (0)20 8047 5000 Registered number: 3888792 www.gsk.com
© Copyright 2024